Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Csenge Advisory Group

Csenge Advisory Group increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.3% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 449 shares of the biopharmaceutical company’s stock after acquiring an additional 49 shares during the period. Csenge Advisory Group’s holdings in Regeneron Pharmaceuticals were worth $432,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. West Paces Advisors Inc. lifted its stake in Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 23 shares in the last quarter. Fortitude Family Office LLC purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $31,000. MCF Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares in the last quarter. Criterion Capital Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $37,000. Finally, BOK Financial Private Wealth Inc. purchased a new position in Regeneron Pharmaceuticals in the 1st quarter worth approximately $37,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have weighed in on REGN. Cantor Fitzgerald reissued a “neutral” rating and set a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. Argus lifted their target price on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Bank of America lifted their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research note on Friday, April 12th. UBS Group lifted their target price on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Finally, StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,038.77.

Regeneron Pharmaceuticals Stock Up 1.7 %

Shares of REGN stock traded up $18.69 during trading on Thursday, reaching $1,089.81. The company’s stock had a trading volume of 225,850 shares, compared to its average volume of 471,265. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The company has a market capitalization of $120.09 billion, a price-to-earnings ratio of 32.09, a P/E/G ratio of 2.17 and a beta of 0.13. The stock’s 50-day moving average price is $1,008.01 and its 200 day moving average price is $961.64. Regeneron Pharmaceuticals, Inc. has a 1-year low of $714.15 and a 1-year high of $1,091.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The business had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the transaction, the executive vice president now owns 12,931 shares in the company, valued at approximately $13,540,179.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the transaction, the executive vice president now owns 12,931 shares in the company, valued at approximately $13,540,179.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The disclosure for this sale can be found here. Insiders sold 63,208 shares of company stock worth $62,514,142 in the last 90 days. Corporate insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.